Key result
Bibliometric analysis of ~600 publications reveals growing ARNI research focused on heart failure and hypertension.
Why the study?
Although ARNI has shown therapeutic benefits across clinical studies in cardiovascular disease, a comprehensive bibliometric review of ARNI research trends and hotspots was needed.
This bibliometric review maps the rapid growth and key contributors in ARNI cardiovascular research from 2000 to 2022, highlighting its primary focus on heart failure and hypertension.
Answers are grounded in this paper and cite their sources.
ARNI research growth reflects expanding clinical interest in HF and hypertension; leaves open gaps in other applications and real-world outcomes.
Cardiovascular disease (CVD) has become a huge challenge for the global public health system due to its high morbidity, mortality and severe economic burden. In recent years, angiotensin receptor neprilysin inhibitor (ARNI), a new class of drugs, has shown good therapeutic effects on CVD patients in several clinical studies, reducing the morbidity and mortality of CVD patients. In this study, we retrieved publications on ARNI research in the cardiovascular field from the Web of Science core collection and analyzed the annual output, spatial and temporal distribution, institutions and authors, core journals, keywords and co-cited literature based on CiteSpace. As a result, 604 publications were retrieved, and the number of annual publications generally increased year by year, with the largest number of articles. The analysis of the co-occurrence of output countries and authors showed that a few developed countries such as the United States, Canada, and United Kingdom are the most active in this field, forming academic groups represented by John Joseph Valentine McMurray and Scott D. Solomon, and New England Journal of Medicine, Cirulation, and Journal of the American College of Cardiology are the most popular journals in the field, with research hotspots focused on ARNI in the treatment of total ejection fraction heart failure, hypertension and its target organ damage, with the potential for future benefit throughout the cardiovascular event chain as research progresses. This study reveals the prospective application of ARNI in the cardiovascular field and the research hotspots, providing broader and deeper guidance for its use in the clinic, which is beneficial to improve the treatment and prognosis of CVD patients.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2022) conducted a review in Cardiovascular Diseases (n=604). Angiotensin Receptor Neprilysin Inhibitor (ARNI) was evaluated on Bibliometric characteristics (annual output, spatial and temporal distribution, institutions, authors, core journals, keywords, co-cited literature). A bibliometric analysis of 604 publications from 2000 to 2022 revealed a significant increase in ARNI research in cardiovascular diseases, primarily focusing on heart failure and hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: